Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 1

Ligneous conjunctivitis in a patient with Crohn′s disease

Authors Graciana Fuentes-Páez, José M Herreras, M del C Méndez, MA Saorni

Published Date March 2008 Volume 2008:2(1) Pages 203—206

DOI http://dx.doi.org/10.2147/OPTH.S2215

Published 17 March 2008

Graciana Fuentes-Páez1, José M Herreras1, M del C Méndez2, MA Saorni1,2

1Ocular Immunology and Uveitis Unit, Institute of Ophthalmobiology (IOBA), University of Valladolid, Valladolid, Spain and Hospital Universitario de Valladolid, Spain; 2Ocular Pathology and Lab Registry “Miguel N. Burnier”, Institute of Ophthalmobiology (IOBA), University of Valladolid, Valladolid, Spain

Objective: Report the case of a patient with Crohn´s disease and ligneous conjunctivitis.

Methods: Interventional case report of a 27-year old female patient, with a 4-year history of Crohn´s disease, was seen for right eye conjunctival ulcer after resolved chemical trauma. Conjunctival biopsy was performed for histopathology, immunofluorescence microscopy, and immunohistochemistry testing.

Results: Microbiology tests were negative for bacteria and fungi. PCR was negative for atypical mycobacteria and Herpes. Ocular Crohn´s disease, Whipple disease, and amyloidosis were ruled out. Immunofluorescence microscopy revealed characteristic IgG κ and λ light chain deposits, and fibrin deposition was confirmed through Lendrum´s Martius, Scarlet, and Blue technique. Endogenous plasminogen levels were normal. Recurrent ulcers did not resolve after treatment with infliximab, but only after four surgeries, topical steroids, 1% cyclosporine, heparin (5000 units/ml), and hyaluronidase (1.5 mg/ml). After 9 months of follow-up, nasal symblepharon was observed as sequela.

Conclusions: We report the case of a patient with unilateral ligneous conjunctivitis, triggered by chemical injury, and Crohn´s disease.

Keywords: Crohn´s disease, immunofluorescence microscopy, ligneous conjunctivitis, plasminogen, ulcerative conjunctivitis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Epidemiological and mortality analysis of older adults with HIV in eastern China

Xie TS, Wu NP

Clinical Interventions in Aging 2013, 8:1519-1525

Published Date: 19 November 2013

Gold nanoparticles as physiological markers of urine internalization into urothelial cells in vivo

Hudoklin S, Zupančič D, Makovec D, Kreft ME, Romih R

International Journal of Nanomedicine 2013, 8:3945-3953

Published Date: 14 October 2013

Women’s awareness and periconceptional use of folic acid: data from a large European survey

Bitzer J, von Stenglin A, Bannemerschult R

International Journal of Women's Health 2013, 5:201-213

Published Date: 26 April 2013

Outcome mapping for health system integration

Tsasis P, Evans JM, Forrest D, Jones RK

Journal of Multidisciplinary Healthcare 2013, 6:99-107

Published Date: 14 March 2013

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011